Cannabidiol (CBD) Cannabinoid
Cannabidiol (CBD) is a complex topic that requires discussion of myriad factors in various disciplines, including agriculture, medicine, pharmacology, and the law. Many differences of opinion compete for legitimacy in these realms, and the attendant rules that attach are in a constant flux from government laws. This training will serve in clarifying the important factors that a patient should know when considering CBD as a therapeutic modality.
A bit of background history is in order, CBD is the primary cannabinoid encountered in European hemp chemovars (aka “chemical varieties”), but in low concentration. In the past, in traditional hashish-growing areas such as Morocco, Lebanon, and Afghanistan, CBD was present in equal measure with Tetrahydrocannabinol (THC), but this has changed over the years.
After the identification of the chemical structures of CBD in 1963 and THC the following year, THC became the subject of intense interest and research, with little attention devoted to CBD. Some even suggested that it was “inactive” merely because it lacked the intoxicating properties of THC. While a few researchers continued to investigate CBD, notably in Israel and Brazil, THC garnered the vast majority of funding dollars and became a target of cannabis breeding.